We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GV-971

News List

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease prnasia
January 17, 2022
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate...
China’s First Innovative Drug for Alzheimer’s Disease: GV-971 Marketed at RMB895 PharmaSources/Dishui Sinan
January 06, 2020
The innovative drug for Alzheimer’s disease (AD)-GV-971 (sodium oligomannurarate) has been officially marketed in China, which is priced at RMB895/box and has attracted much attention of the pharmaceutical practitioners.